Evaluating the Efficacy of a Small Interfering Ribonucleic Acid Molecule, Givosiran, in Treating Acute Intermittent Porphyria: A Systematic Review

Acute intermittent porphyria (AIP) is a severe multiorgan dysfunction disorder that can be fatal if not treated promptly. The newest treatment modality involving small interfering RNA (siRNA) molecules, givosiran, is administered for AIP. Although it has very beneficial effects in treating attacks o...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Priyansh, Midha, Sidharth, Shukla, Surmai, Dhamija, Divyanshu, Bello, Adedamola O, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353265/
https://www.ncbi.nlm.nih.gov/pubmed/37469824
http://dx.doi.org/10.7759/cureus.40585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353265/
https://www.ncbi.nlm.nih.gov/pubmed/37469824
http://dx.doi.org/10.7759/cureus.40585

Ejemplares similares